First Trust Advisors LP trimmed its position in shares of Glaukos Corporation (NYSE:GKOS) by 47.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 23,407 shares of the medical instruments supplier’s stock after selling 21,557 shares during the quarter. First Trust Advisors LP owned about 0.07% of Glaukos worth $772,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in GKOS. California Public Employees Retirement System boosted its holdings in shares of Glaukos by 10.5% during the 2nd quarter. California Public Employees Retirement System now owns 8,400 shares of the medical instruments supplier’s stock valued at $348,000 after acquiring an additional 800 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Glaukos by 1.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock worth $2,915,000 after purchasing an additional 994 shares during the period. Ameritas Investment Partners Inc. lifted its stake in shares of Glaukos by 93.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Glaukos by 3.7% in the 2nd quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock worth $1,455,000 after purchasing an additional 1,237 shares during the period. Finally, Navellier & Associates Inc lifted its stake in shares of Glaukos by 4.9% in the 2nd quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock worth $1,381,000 after purchasing an additional 1,567 shares during the period. 99.23% of the stock is currently owned by institutional investors.
Glaukos Corporation (GKOS) traded down $0.02 during midday trading on Thursday, reaching $25.53. 407,300 shares of the company’s stock traded hands, compared to its average volume of 640,192. The stock has a market capitalization of $883.15, a price-to-earnings ratio of 212.92 and a beta of 1.02. Glaukos Corporation has a 52 week low of $23.44 and a 52 week high of $52.49.
Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.06. The company had revenue of $40.41 million during the quarter, compared to analyst estimates of $38.69 million. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. Glaukos’s quarterly revenue was up 36.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 earnings per share. sell-side analysts predict that Glaukos Corporation will post -0.03 EPS for the current fiscal year.
A number of equities research analysts have commented on the stock. Stifel Nicolaus restated a “buy” rating on shares of Glaukos in a research note on Thursday, September 14th. BidaskClub upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $60.00 price objective on shares of Glaukos in a research report on Tuesday, November 7th. Piper Jaffray Companies reiterated a “buy” rating and set a $38.00 price objective on shares of Glaukos in a research report on Friday, September 15th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $54.00 price objective on shares of Glaukos in a research report on Friday, September 1st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $46.57.
In related news, CFO Joseph E. Gilliam bought 2,100 shares of the stock in a transaction dated Wednesday, November 22nd. The stock was purchased at an average cost of $23.84 per share, with a total value of $50,064.00. Following the completion of the purchase, the chief financial officer now owns 102,100 shares of the company’s stock, valued at $2,434,064. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 16.40% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Glaukos Corporation (GKOS) Position Reduced by First Trust Advisors LP” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.thelincolnianonline.com/2017/12/07/glaukos-corporation-gkos-position-reduced-by-first-trust-advisors-lp.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.